Tuesday, June 01, 2010

Extension study with FIRMAGON® (degarelix) showed continued benefits for prostate cancer patients beyond one year

|More|
Monday, May 10, 2010

Ferring acquires LYSTEDA™ from Xanodyne Pharmaceuticals, Inc.

|More|
Monday, April 19, 2010

Consider the "whole-man" when treating prostate cancer

|More|
Monday, April 19, 2010

Wake Up to Nocturia Studies Reinforce Serious Associated Risk of Nocturia

|More|
Thursday, April 01, 2010

Xanodyne and Ferring announce co-promote for ZIPSOR™

|More|
 

By using the service, you agree to the following:

Your email address and the recipient's email address will be used for transmission purposes only - to inform the addressee about the sender, or for sending a message in the event of a transmission error. Both email addresses will be deleted from our system after a short period.